German site
Our portfolio
Below is a list of products available in our portfolio. It is not exhaustive and brand names and availability may vary country to country. Patients should contact their local healthcare professional if they have any questions regarding the medication referenced here.
Cardiovascular
Inderal®
(also Inderalici®) propranolol
Tenoretic®
(also Tenoret®) atenolol + chlorthalidone
Tenormin®
(also Tenormine®) atenolol
Zestoretic®
(also Acercomp®) lisinopril + hydrochlorothiazide
Zestril®
(also Acemin®) lisinopril
Endocrinology
Ghryvelin™
(also Macimorelin) macimorelin
Rocaltrol®
calcitriol
Synacthen®
tetracosactide
Synacthen® Depot
tetracosactide acetate
Neurology
Anaprox®
(also Apranax®)
naproxen sodium
Frisium®
(also Castilium®, Noiafren®, Sentil®, Urbadan®, Urbanil®, Urbanol® and Urbanyl®)
clobazam
Gardenal®
phenobarbital
Naprosyn®
(also Naprometin®, Naprosyn SR®/Naprosyn CR®/Naprosyn LE®/EC-Naprosyn®, Naprosyne®, Naxen® and Proxen®)
naproxen
Stemetil®
prochlorperazine
Tercian®
cyamemazine
Toradol®
(also Tora-dol®, Taradyl®, Taradol®, Tarasyn® and Lixidol®)
ketorolac
Valium®
diazepam
Xadago®
safinamide
Oncology
Dipentum®
olsalazine
Kytril®
(also Kevatril®)
granisetron
Leustat®
(also Leustatin®) cladribine
Other
Famvir®
famciclovir
Healthcare professionals can contact medinfo@pharmanovia.com for all medical related enquiries, including supply questions.
Reporting side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Adverse event reporting
Adverse events should be reported. UK reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to medinfo@pharmanovia.com
For those outside of the UK please follow your local regulatory guidance.